CRISPR Therapeutics' stock faces challenges with slow Casgevy adoption and competition. See how CRSP stock remains a cautious ...

One-time gene therapies also offer a potential cure for SCD. Two have recently been approved in the U.S.: Lyfgenia (lovotibeglogene autotemcel) and Casgevy (exagamglogene autotemcel). Each of these ...

At risk of defaulting on financial commitments, gene therapy firm bluebird bio has agreed to sell itself to private equity firms at a knockdown price. The FDA is scrutinising reports of ...

The U.S. Food and Drug Administration granted approval to Casgevy and Lyfgenia as the first cell-based gene therapies for treating sickle cell disease among patients aged 12 or older in 2024. Casgevy ...

Casgevy and Lyfgenia, the two cell-based gene therapies approved by the FDA, utilise the CRISPR/Cas9 genome editing technology. Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR ...

The FDA approved Lyfgenia and Vertex Pharmaceuticals' (VRTX) Casgevy for the treatment of sickle cell disease in December 2023. Casgevy was co-developed with CRISPR Therapeutics (CRSP).

The biotech's Casgevy, a treatment for sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT), which it developed with Vertex Pharmaceuticals, is now approved in the U.S ...

This latest gene therapy offering is Casgevy, which treats sickle cell disease and transfusion-dependent beta thalassemia, a blood disorder that reduces the production of hemoglobin.

The company is anticipating continued growth in fiscal 2025 with the approval of JOURNAVX, the launch of its fifth CF medicine, ALYFTREK, and the continuing global acceptance of CASGEVY ...